Haemophilia & Bleeding Disorders Nursing

Comprehensive Clinical Guide for GCC Nurses

GCC Edition  |  Updated April 2026  |  Evidence-Based Practice
Bleeding Disorders Overview
🧬 Haemophilia A
  • Deficiency: Factor VIII (FVIII)
  • Inheritance: X-linked recessive
  • Incidence: ~1 in 5,000 male births
  • Most common severe inherited coagulation disorder
  • Females are carriers; rarely symptomatic unless lyonisation skewed
  • Carrier females may have low FVIII levels — screen them
APTT prolonged PT normal TT normal
🧬 Haemophilia B (Christmas Disease)
  • Deficiency: Factor IX (FIX)
  • Inheritance: X-linked recessive
  • Incidence: ~1 in 30,000 male births
  • Clinically identical to Haemophilia A — distinguished by factor assay
  • Named after Stephen Christmas, first diagnosed patient (1952)
APTT prolonged PT normal TT normal
Severity Classification
SEVERE
Severe
<1%
  • Spontaneous joint/muscle bleeds
  • Haemarthrosis from childhood
  • Requires prophylaxis
MODERATE
Moderate
1–5%
  • Bleeds with mild trauma
  • Occasional spontaneous bleeds
  • May not need prophylaxis
MILD
Mild
5–40%
  • Bleeds with significant trauma/surgery
  • May be undiagnosed for years
  • DDAVP may be adequate
Clinical Features
🦴 Haemarthrosis (Joint Bleeds)
  • Most common: knees, elbows, ankles
  • Warmth, swelling, pain, reduced range of motion
  • Repeated bleeds → chronic haemophilic arthropathy
  • Target joint: same joint bled 3+ times in 6 months
  • Synovitis → cartilage destruction → disability
💪 Muscle Bleeds
  • Iliopsoas bleed: hip flexion pain, groin/back pain, femoral nerve palsy
  • Compartment syndrome risk with forearm/calf bleeds
  • Monitor neurovascular status (pulses, sensation, movement)
  • CT/ultrasound to assess extent
🧠 Intracranial Bleeding
EMERGENCY: Any headache, confusion, vomiting, neurological deficit — treat IMMEDIATELY with factor to 100% before imaging if delay anticipated.
  • Most dangerous complication — 30% of haemophilia deaths
  • Can be spontaneous in severe disease
  • Symptoms: severe headache, drowsiness, fitting, focal signs
  • CT head + neurosurgical referral + haematology input
🩸 Other Bleeding Sites
  • Mucosal: epistaxis, gum bleeding, haematuria
  • GI bleeding: haematemesis, melaena
  • Soft tissue haematomas
  • Delayed surgical bleeding (hours/days post-op)
  • Neonatal: intracranial bleed at delivery, cephalhaematoma, circumcision bleed
von Willebrand Disease (vWD)
Most common hereditary bleeding disorder — affects ~1% of population. Both males and females equally affected.
Type 1
  • Partial quantitative deficiency of vWF
  • Autosomal dominant
  • Commonest type (75%)
  • Responds well to DDAVP
  • Mild mucocutaneous bleeding
Type 2
  • Qualitative defect in vWF (A/B/M/N subtypes)
  • Autosomal dominant mostly
  • DDAVP contraindicated in type 2B (thrombocytopenia worsening)
  • Requires vWF concentrate
Type 3
  • Complete absence of vWF
  • Autosomal recessive
  • Severe — resembles haemophilia A
  • DDAVP ineffective
  • vWF/FVIII concentrate required
Platelet Disorders
🔵 ITP — Immune Thrombocytopenic Purpura
  • Autoimmune destruction of platelets
  • Platelet count <100 × 10⁹/L
  • Petechiae, purpura, bruising, mucosal bleeding
  • Treatment: corticosteroids, IVIG, TPO agonists, rituximab, splenectomy
🔵 Hereditary Platelet Disorders
  • Glanzmann's thrombasthenia: absent GPIIb/IIIa — platelet aggregation failure — autosomal recessive — platelet transfusion/rFVIIa
  • Bernard-Soulier syndrome: absent GPIb — platelet adhesion failure — large platelets — autosomal recessive
Coagulation Screen Interpretation
ConditionPTAPTTTTFibrinogenPlatelets
Haemophilia A/BNormalProlonged ↑NormalNormalNormal
vWD (most types)Normal+/- ProlongedNormalNormalNormal
Warfarin / Vit K deficiencyProlonged ↑+/- ProlongedNormalNormalNormal
DICProlonged ↑Prolonged ↑Prolonged ↑Low ↓Low ↓
ITPNormalNormalNormalNormalLow ↓
Heparin therapyNormalProlonged ↑Prolonged ↑NormalNormal
Glanzmann's/BSSNormalNormalNormalNormalNormal count
Key nursing point: A prolonged APTT with normal PT in a male patient = haemophilia A or B until proven otherwise. Always send mixing studies (1:1 normal plasma) — correction = factor deficiency; no correction = inhibitor.
Factor Replacement Therapy
💉 Factor VIII Concentrates
Haemophilia A
  • Plasma-derived: Octanate, Haemate P (contains vWF — useful for vWD)
  • Recombinant (preferred): Advate, Kogenate FS, Nuwiq, Kovaltry
  • Recombinant preferred — no blood-borne infection risk
  • Standard half-life: 8–12 hours → dosing 2–3x/week
  • Store at 2–8°C or room temperature per product instructions
💉 Factor IX Concentrates
Haemophilia B
  • Plasma-derived: Mononine, Immunine
  • Recombinant (preferred): BeneFIX, Rixubis, Idelvion
  • Half-life 18–24 hours → less frequent dosing
  • Volume of distribution larger than FVIII — dosing formula differs
Dosing Formulae
Haemophilia A: Dose (IU) = Weight (kg) × Desired Rise (%) × 0.5
Haemophilia B: Dose (IU) = Weight (kg) × Desired Rise (%) × 1.0
Example — Haemophilia A
Patient weight70 kg
Desired FVIII rise50% (moderate bleed)
Dose70 × 50 × 0.5 = 1,750 IU
Repeat dose in8–12 hours
Example — Haemophilia B
Patient weight70 kg
Desired FIX rise50% (moderate bleed)
Dose70 × 50 × 1.0 = 3,500 IU
Repeat dose in18–24 hours
Target Factor Levels by Clinical Situation
Clinical SituationTarget Factor LevelDurationFrequency
Minor bleed (haemarthrosis, small muscle)30–50%1–3 daysOnce or twice
Moderate bleed (major muscle, mouth, tongue)50–80%3–5 daysEvery 8–24h
Life/limb-threatening bleed (ICH, neck, iliopsoas)80–100%7–14 daysEvery 8–12h (FVIII)
Major surgery (pre-operative)100%Until healingContinuous infusion or bolus q8h
Minor surgery / dental extraction50%1–3 daysSingle dose + tranexamic acid
Prophylaxis (severe haemophilia)>1% troughLifelong3x/week or EOD
Half-Lives & Extended Half-Life (EHL) Products
⏱️ Standard Half-Lives
Factor VIII8–12 hours
Factor IX18–24 hours
Repeat dose neededFVIII q8–12h; FIX q24h
Higher peak, shorter duration — requires frequent IV access
⏱️ Extended Half-Life (EHL) Products
  • EHL FVIII: Elocta (rFVIIIFc) — half-life ~19h, twice weekly
  • EHL FIX: Alprolix (rFIXFc) / Idelvion — half-life up to 102h, once weekly or fortnightly
  • Major benefit for GCC patients: fewer infusions, better adherence
  • Reduced burden for families with multiple affected children
  • Especially valuable in Ramadan — fewer daily infusions
Inhibitor Development
Inhibitors are neutralising IgG antibodies against infused factor — the most serious treatment complication of haemophilia.
  • 15–30% of severe haemophilia A develop inhibitors
  • 1–5% of haemophilia B develop inhibitors
  • High titre: >5 Bethesda Units (BU) — standard factor ineffective
  • Low titre: <5 BU — high-dose factor may still work
  • Bethesda assay / Nijmegen modification used for measurement
Bypassing Agents for Inhibitor Patients
rFVIIa (NovoSeven)90–120 mcg/kg IV q2–3h
aPCC (FEIBA)50–100 IU/kg q8–12h (max 200 IU/kg/day)
Caution: Never combine rFVIIa and aPCC — risk of thrombosis/DIC.
Factor Administration — Nursing Technique
1
Reconstitution

Warm vials to room temperature. Use provided diluent. Gently rotate — do NOT shake (denaturation risk). Inspect for particulates.

2
IV Administration

Peripheral IV or implanted port (PAC/portacath). Slow IV push — typical rate 2–3 mL/min (FVIII). Check product PI for FIX rate limits.

3
Post-Infusion

Document: lot number, expiry, dose given, time, site. Flush with normal saline. Observe 20 min for allergic reaction.

4
Monitoring

Post-infusion factor level at 15 min (peak) and 1h (in vivo recovery). Monitor bleed response. Report inadequate response immediately — suspect inhibitor.

Non-Factor Treatments & Prophylaxis
💊 Emicizumab (Hemlibra) — Game Changer
Bispecific antibody that bridges FIXa and FX, mimicking FVIII function — subcutaneous injection. Licensed for Haemophilia A with AND without inhibitors.
MechanismBridges FIXa + FX (FVIII bypass)
RouteSubcutaneous injection
Dosing optionsWeekly / Fortnightly / Monthly
Loading dose3 mg/kg SC weekly × 4 weeks
Maintenance1.5 mg/kg weekly (or 3 mg/kg 2-weekly)
Half-life~4–5 weeks
Nursing Considerations
  • Teach SC injection technique — patient/carer self-administration
  • Rotate injection sites: abdomen / thigh / upper arm
  • TMA (thrombotic microangiopathy) risk if aPCC used concurrently — avoid aPCC >100 IU/kg/day total >24h
  • Monitor for TMA: haematuria, thrombocytopenia, rising creatinine
  • APTT is artificially shortened on emicizumab — do NOT use APTT to monitor
  • GCC benefit: monthly dosing option ideal for Ramadan/Hajj
Desmopressin (DDAVP)
For mild Haemophilia A & vWD Type 1
MechanismReleases stored FVIII & vWF from endothelium
IV/SC dose0.3 mcg/kg in 50 mL NS over 30 min
IntranasalStimate: 150 mcg (<50kg) / 300 mcg (≥50kg)
Response monitoringFVIII level at 1h post-dose
TachyphylaxisAfter 3 doses — storages depleted
Hyponatraemia risk: DDAVP causes water retention (ADH effect). Fluid restrict to 1L/24h post-dose. Monitor serum sodium — especially in children, elderly, cardiac patients.
Contraindications
  • vWD type 2B (worsens thrombocytopenia)
  • Haemophilia B (no FVIII stores to release)
  • Severe haemophilia A (insufficient stores)
  • Cardiovascular disease (vasoactive effects)
  • Children under 2 years
Tranexamic Acid
Antifibrinolytic agent — prevents clot breakdown. Excellent for mucosal and surface bleeding.
MechanismInhibits plasminogen activators → prevents fibrinolysis
Oral dose15–25 mg/kg TDS (adults: 1g TDS)
IV dose10 mg/kg TDS
Mouthwash10 mL of 5% solution QDS × 5–7 days (dental)
Best forDental, mucosal, epistaxis, menorrhagia
NEVER use tranexamic acid in haematuria — risk of obstructive clot formation in the ureter leading to renal colic and urinary obstruction. Ensure adequate hydration and use factor only for haematuria.
  • Available in GCC formularies — widely accessible
  • Halal-compliant — no animal-derived components
  • Often combined with DDAVP or factor therapy
Primary Prophylaxis — Prevention of Joint Disease
Gold standard for severe haemophilia A & B: Start factor prophylaxis before first joint bleed, ideally by age 2–3 years (joint-protective). Goal: trough factor level >1%.
Standard prophylaxis (Haem A)25–40 IU/kg 3x/week or EOD
Standard prophylaxis (Haem B)40–60 IU/kg 2x/week
EHL FVIII prophylaxis50 IU/kg twice weekly
EHL FIX prophylaxis40–75 IU/kg once weekly
Emicizumab prophylaxis1.5 mg/kg weekly SC
Nursing Role in Prophylaxis
  • Educate family on importance of compliance
  • Teach home infusion technique (3–5 years of age)
  • Monitor joint health: annual joint score (Pettersson score/Haemophilia Joint Health Score)
  • Arrange physiotherapy for joint rehabilitation
  • Breakthrough bleeds on prophylaxis = inhibitor screen
Fitusiran & Concizumab (Emerging Therapies)
Fitusiran (Alhemo)
  • siRNA — silences antithrombin synthesis
  • Monthly SC injection
  • For Haemophilia A & B with/without inhibitors
  • Risk of thrombosis — strict monitoring required
Concizumab (Alhemo)
  • Anti-TFPI antibody — blocks tissue factor pathway inhibitor
  • Daily SC injection
  • Works for Haemophilia A, B and inhibitor patients
  • Expanding formulary options in GCC
Acute Bleed Management
Core Principle: Treat within 2 hours of bleed onset — early treatment prevents progression, reduces factor required, preserves joint function.
🧊 RICE Principle + PROMPT Factor Treatment
RestImmobilise affected joint/limb immediately
IceIce pack (wrapped in cloth) 15–20 min — reduces swelling
CompressionElastic bandage — not too tight
ElevationElevate limb above heart level
PROMPT factor therapy is paramount. RICE alone is insufficient. Administer appropriate factor within 2 hours of bleed onset. Do not delay for investigations.
  • NSAIDs/Aspirin/Ibuprofen — STRICTLY contraindicated (platelet inhibition)
  • Paracetamol/Codeine for analgesia
  • COX-2 inhibitors (celecoxib) — safer alternative in chronic arthropathy
Specific Bleed Sites
🦴 Haemarthrosis (Joint Bleed)
  • Most common: knee (45%) → elbow (30%) → ankle (15%)
  • Signs: warmth, swelling, stiffness, flexion posture, painful ROM
  • Give factor immediately (target 30–50% for acute bleed)
  • Rest in position of comfort (slight flexion for knee)
  • Aspiration: do NOT aspirate in community — hospital only, under factor cover
  • Physiotherapy after resolution — range of motion exercises
  • Repeated bleeds in same joint = target joint — escalate to haematologist
💪 Muscle Bleeds
  • Iliopsoas bleed: groin/hip/back pain, hip held in flexion, femoral nerve stretch sign positive
  • Femoral nerve palsy risk: numbness anterior thigh, quadriceps weakness
  • Target: 80% factor — admit for monitoring
  • CT/MRI to confirm and quantify
  • Compartment syndrome risk: calf, forearm bleeds — hourly neurovascular obs
  • Monitor: distal pulses, cap refill, sensation, power (6Ps)
🧠 Intracranial Haemorrhage (ICH) — EMERGENCY
LIFE-THREATENING EMERGENCY. Any head injury or new headache in a person with haemophilia = treat FIRST, investigate second.
Warning Symptoms
  • Sudden severe headache ("worst headache of life")
  • Vomiting, drowsiness, confusion
  • Seizures
  • Focal neurological deficits
  • Neck stiffness
Immediate Management
  1. Administer factor concentrate IMMEDIATELY — target 100%
  2. Call senior haematologist
  3. Urgent CT head (after factor given if delay <15 min)
  4. Neurosurgical referral if haematoma
  5. ICU involvement for monitoring
  6. Continue factor for minimum 14 days
🦷 Dental Procedures
  • Pre-procedure: DDAVP (mild HemA/vWD1) OR factor to 50%
  • Tranexamic acid mouthwash 10 mL QDS for 5–7 days post-extraction
  • Tranexamic acid oral 1g TDS × 5 days
  • Topical thrombin/fibrin sealant at socket
  • Coordinate with haemophilia nurse specialist pre-procedure
  • Nerve block injections require factor cover — haematoma risk
  • Regular dental hygiene essential — prevent need for procedures
💋 Mucosal & Other Bleeds
  • Epistaxis: first aid pressure 20 min; tranexamic acid oral; nasal cautery under factor cover if persistent
  • Gum bleeding: tranexamic acid mouthwash; local pressure; dental referral
  • GI bleed: factor replacement + GI endoscopy under cover; tranexamic acid IV
  • Haematuria: hydration 3L/24h; factor if severe; NO tranexamic acid
  • Menorrhagia: tranexamic acid + hormonal therapy; consider vWD/carrier state
Trauma Assessment Protocol
1
Treat first — always

Administer factor at 100% immediately for any significant trauma. Do not wait for imaging results.

2
ABCDE assessment

Standard trauma assessment alongside haemostatic management. Secure IV access. Cross-match blood.

3
Imaging

CT head for any head injury, even minor. Ultrasound/MRI for soft tissue and muscle bleeds. X-ray for joint assessment.

4
Haematology notification

Alert on-call haematologist for any significant trauma. Inhibitor screen if poor response to initial factor dose.

Medications to AVOID: Aspirin, NSAIDs, IM injections (use SC/IV routes only), arterial punctures without prolonged pressure, rectal temperature/procedures (risk of bleeding).
Comprehensive Care Centre & Home Treatment
🏥 Haemophilia Nurse Specialist Role
  • Lead factor education sessions for patients and families
  • Home therapy programme training and certification
  • Prophylaxis monitoring and dose optimisation
  • Inhibitor surveillance — annual Bethesda assay
  • Joint assessment using validated scoring tools
  • Maintain haemophilia registry and treatment records
  • Coordinate multidisciplinary care: haematologist/physiotherapist/orthopaedic/dentist
  • Emergency planning and patient safety netting
  • School liaison for children with haemophilia
  • Psychological support for chronic disease burden
  • Travel and Hajj preparation advice
  • Research and clinical trial support
Home Therapy Programme
1
Assessment for suitability

Patient/carer motivation, visual acuity, manual dexterity, home storage facilities (fridge), sharps disposal access.

2
Vein access training

Peripheral venepuncture technique. Vein preservation strategies. Central venous access device (portacath) insertion for small/difficult veins — common in young children.

3
Reconstitution and administration

Aseptic technique. Product-specific reconstitution. Administration rate. Sharps safety — never recap needles. Sharps disposal containers.

4
Documentation and stock management

Bleed diary/app (e.g., HaemoAssist). Treatment log: date/time/reason/dose/lot number. Cold chain management. Supply ordering and emergency stock.

5
Competency sign-off and review

Witnessed administration. Annual competency reassessment. 24/7 haemophilia nurse helpline contact provided.

Physiotherapy & Joint Care
🏊 Recommended Physical Activities
  • Swimming — excellent low-impact, builds muscle
  • Cycling — knee-protective, cardiovascular fitness
  • Walking, yoga, pilates
  • Golf, fishing, bowling
  • Controlled gym weights — with physiotherapy guidance
  • Contact sports (rugby, boxing, martial arts) — AVOID
  • Football (soccer) — high risk in severe haemophilia
🦿 Joint Assessment & Rehabilitation
  • Target joint: >3 bleeds in 6 months — intensive physiotherapy + consider prophylaxis intensification
  • Haemophilia Joint Health Score (HJHS) — annual assessment
  • Ultrasound joint imaging — synovitis detection
  • Radiosynovectomy for chronic synovitis (radioisotope injection)
  • Orthopaedic surgery (joint replacement) under full factor cover
  • Weight management crucial — reduces joint loading
Inhibitor Management — Immune Tolerance Induction (ITI)
Immune Tolerance Induction (ITI): High-dose factor FVIII given daily (50–200 IU/kg/day) for 12–24 months to desensitise immune system and eradicate inhibitors. Success rate ~70% in good prognosis patients.
Good prognosis factorsPeak inhibitor <200 BU, starting titre <10 BU
High-dose ITI200 IU/kg/day (Bonn protocol)
Low-dose ITI50 IU/kg 3x/week (Malmö low-dose)
DurationUntil inhibitor <0.6 BU and FVIII recovery normalises
MonitoringMonthly Bethesda assay + FVIII recovery
GCC formulary challenge: ITI is extremely expensive — high factor usage for 1–2 years. Access varies across GCC countries. KFSH Riyadh and Hamad Medical Centre Doha have established ITI programmes.
  • Central venous access essential for ITI
  • Bypass therapy (rFVIIa/aPCC) for breakthrough bleeds during ITI
  • Emicizumab as concurrent prophylaxis during ITI — reduces bleed burden
Surgical Planning
PhaseActionTarget
Pre-operative (1 week)Factor level, inhibitor screen, FBC, coag screen, G&SBaseline established
Pre-operative (day of)Factor infusion 30–60 min pre-op100% factor level
Intra-operativeContinuous factor infusion or bolus q4–6h; anaesthetic team awareMaintain >80%
Post-operative day 1–3Factor q8–12h; surgical site monitoring; drain output50–80%
Post-operative day 4–14Factor q12–24h; physiotherapy starts; wound assessment30–50%
After day 14Return to standard prophylaxis regimenTrough >1%
Emergency Preparedness & Travel
🆘 Emergency Card & Alert Bracelet
  • Every patient must carry a haemophilia emergency card (in Arabic and English)
  • Card includes: diagnosis, severity, factor product, inhibitor status, haemophilia centre contact
  • Medical alert bracelet/necklace — worn at all times
  • Emergency contacts: haemophilia nurse specialist, on-call haematologist
  • WFH (World Federation of Hemophilia) global treatment directory
✈️ Travel with Factor Concentrates
  • Obtain doctor's letter on hospital letterhead (Arabic + English)
  • Factor must be in original packaging with pharmacy label
  • Cold chain: insulated bag with ice packs for travel; factor stored 2–8°C
  • Carry at least 3–5 days extra supply above planned need
  • WFH treatment centre directory for destination country
  • Inform airline in advance — sharps/needles in cabin baggage
  • Travel insurance: disclose haemophilia, ensure emergency treatment covered
Adolescent Transition to Adult Services
  • Transition planning begins at age 14–16
  • Young person takes increasing ownership of self-management
  • Education: independence with home therapy, vein care
  • Vocational guidance: careers compatible with haemophilia
  • Sexual health: passing on the gene — genetics counselling
  • Mental health screening: anxiety/depression common in chronic disease
  • Substance misuse risk — illicit drug IV use destroys veins
  • Transition clinic: joint paediatric/adult haematology appointment
  • Youth ambassador programmes (WFH/national societies)
  • HCV/HIV testing if diagnosed before 1992 (contaminated products era)
GCC Haemophilia Context
🧬 Consanguinity & Genetic Prevalence
Consanguineous marriage (first-cousin marriage) rates in GCC: Saudi Arabia ~30–40%, UAE ~25–30%, Qatar ~35–40% — significantly higher than global averages. This elevates prevalence of autosomal recessive conditions and increases carrier frequency.
  • Haemophilia A & B: X-linked — consanguinity does not directly increase frequency but increases chance of carrier mothers having affected children
  • vWD type 3: autosomal recessive — significantly more common in GCC due to consanguinity
  • Glanzmann's thrombasthenia: particularly prevalent in Jordanian and Arab populations — autosomal recessive
  • Bernard-Soulier syndrome: elevated frequency in consanguineous families
  • Carrier testing essential for sisters/daughters of haemophilia patients
  • Factor VIII/IX gene mutation analysis available in GCC reference labs
  • Preimplantation Genetic Testing (PGT) available in select GCC centres for haemophilia
  • Premarital genetic screening programmes: Saudi Arabia, UAE, Qatar — mandatory for some conditions, voluntary for others
National Haemophilia Registries & Centres
Haemophilia Centres (GCC)
Saudi ArabiaKFSH&RC Riyadh; King Abdullah Medical City, Makkah; King Fahad Hospital
QatarHamad Medical Corporation, Doha (National Haemophilia Centre)
UAESheikh Khalifa Medical City Abu Dhabi; Tawam Hospital Al Ain
KuwaitKuwait Cancer Control Centre Haemophilia Unit
BahrainSalmaniya Medical Complex
OmanRoyal Hospital Muscat
Haemophilia Societies & Registries
  • Saudi Haemophilia Society (SHS) — national registry, patient support, annual conference
  • Emirates Haemophilia Society (EHS) — UAE registry, awareness campaigns
  • Qatar Haemophilia Society
  • WFH (World Federation of Hemophilia) — global registry, treatment support
  • WFH treatment fund provides factor to lower-resource settings in region
Neonatal Diagnosis
  • Family history of haemophilia → plan delivery at haemophilia centre or with haematology support
  • Cord blood sampling at birth: FVIII and FIX levels
  • FIX levels physiologically low at birth — may need repeat at 6 months
  • Vitamin K given at birth (IM route acceptable with precaution in at-risk neonates)
  • AVOID vacuum extraction, forceps delivery, fetal scalp electrodes in suspected haemophilia
  • Circumcision should NOT be performed until haemophilia excluded — cultural sensitivity required when discussing with families
  • Neonatal ICH can occur — neonatal team alert essential
  • Head ultrasound at birth for at-risk neonates
  • Carrier mothers: FVIII/vWF levels often halved during pregnancy — advise on peripartum management
  • Carrier diagnosis: female relatives should be tested proactively
Girls & Women with Bleeding Disorders
Often under-diagnosed: vWD affects both sexes equally. Carrier females may have FVIII levels 30–70% — symptomatic. Heavy menstrual bleeding (HMB) is the commonest presentation in females.
  • vWD: commonest bleeding disorder in women — accounts for majority of unexplained HMB
  • Haemophilia carrier females: mean FVIII ~50% — can have levels <40% (symptomatic)
  • Screen with FVIII/FIX level + vWF antigen + vWF activity (Ristocetin cofactor)
  • Treatment: DDAVP, tranexamic acid, hormonal therapy (combined OCP/Mirena)
  • Obstetric risks: postpartum haemorrhage (PPH) risk elevated
  • Epidural/spinal anaesthesia: safe if FVIII/FIX >50%
  • Genetics counselling: 50% chance of passing haemophilia gene to sons (affected) or daughters (carriers)
  • GCC cultural context: disclosure to husband/family of carrier status can be psychologically complex — support from haemophilia nurse/counsellor essential
Religious & Cultural Considerations
🌙 Ramadan & Factor Administration
  • Oral medications (tranexamic acid) can be taken at suhoor/iftar
  • Subcutaneous injections (emicizumab, DDAVP SC) are permissible during fasting by most Islamic scholars (injection ≠ eating)
  • IV infusions: fatwa varies — most scholars permit for medical necessity
  • Prophylaxis schedule adjustment: switch to EOD or fortnightly EHL products to reduce infusion burden
  • Discuss Ramadan plan with patient and haematologist in advance
  • Fluid restriction around DDAVP doses — be mindful of fasting state (hyponatraemia risk higher)
🕋 Hajj & Haemophilia
  • Advance planning at least 3 months before Hajj/Umrah season
  • Calculate factor requirements for 2–4 weeks + emergency supply
  • Liaise with Hajj Ministry Medical Mission for factor storage at Mina camps
  • Haemophilia Saudi Society: register patients for Hajj medical support
  • Cold storage for factor at Hajj accommodations — liaise with hotel/camp
  • Emicizumab (monthly dosing) ideal for Hajj period — single dose before departure
  • Emergency haemophilia care available at Noor Specialist Hospital and King Abdullah Medical City, Makkah
🕌 Halal Factor Concentrates
Halal compliance: Some plasma-derived factor concentrates use porcine (pig-derived) gelatin as a stabiliser. Recombinant products are generally free of animal-derived components and are preferred as halal-compliant.
  • Recombinant FVIII (Advate, Kogenate, Nuwiq): no animal-derived stabilisers — halal-compliant
  • Recombinant FIX (BeneFIX, Rixubis): halal-compliant
  • Emicizumab: synthetic bispecific antibody — halal-compliant
  • Plasma-derived concentrates: check product PI for excipients (gelatin content)
  • Islamic Fiqh Council: in cases of necessity (darura), non-halal medicines are permitted if no halal equivalent available and life is at risk
  • Document patient's preference in care plan
  • GCC formularies increasingly stocking recombinant products as first line
  • Discuss with patient and family — religious scholars may provide individual guidance
Factor Dose Calculator
Quick Presets:
GCC Haemophilia Nursing Guide  |  For educational purposes — always refer to local formulary and haematology guidelines  |  April 2026